KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical Program.

Andres J Yarur, Millie D Long, Joana Torres, Neilanjan Nandi, Raymond K Cross, Arcangelo M Abbatemarco, David Blanco, Wojciech Niezychowski, Catherine Crosby, Joseph Wu, Gokul Pradeep, Martina Goetsch, Remo Panaccione

Am J Gastroenterol 120(11) 2611-2622

PMID39878434
PMCIDPMC12570604
DOI10.14309/ajg.0000000000003330
发表日期2025-01-29
入排依据:未发现恶性肿瘤人群证据。
已检查 5 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 multi panel km。
摘要

摘要

INTRODUCTION: High body mass index (BMI) may reduce ulcerative colitis (UC) treatment efficacy. Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate 1,4,5 receptor modulator for the treatment of moderately to severely active UC. This post hoc analysis assessed treatment outcomes according to BMI in ELEVATE UC 52 and ELEVATE UC 12. METHODS: Patients receiving etrasimod 2 mg QD or placebo were stratified by BMI: <25, 25-30, and >30 kg/m 2 . Efficacy and safety were assessed at weeks 12 (pooled data) and 52 (ELEVATE UC 52 only) in addition to biomarkers assessments from week 0-12. RESULTS: For BMI <25 (N = 443) and 25-30 kg/m 2 (N = 217) subgroups, more patients receiving etrasimod vs placebo achieved clinical remission at weeks 12 (BMI <25 kg/m 2 : 27.9% vs 13.3%; 25-30 kg/m 2 : 28.5% vs 10.0%; all P < 0.001) and 52 (BMI <25 kg/m 2 : 30.8% vs 10.0%; 25-30 kg/m 2 : 33.3% vs 6.3%; all P < 0.0001), and also for all other efficacy end points ( P < 0.05). In the BMI >30 kg/m 2 subgroup (N = 127), more patients receiving etrasimod vs placebo achieved clinical remission at week 52 (36.5% vs 3.9%; P < 0.0001) and most other efficacy end points at weeks 12 and 52 (all P < 0.05). Overall, regardless of baseline BMI, numerically lower fecal calprotectin levels were observed with etrasimod vs placebo in treatment responders. The safety profile of etrasimod was consistent between BMI subgroups. DISCUSSION: A high BMI did not significantly affect efficacy and safety outcomes of etrasimod (NCT03945188; NCT03996369).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. Primary and secondary efficacy end points assessed at week 12 a (ELEVATE UC 52 and ELEVATE UC 12) and at week 52 (ELEVATE UC 52 only), stratified by baseline BMI (FAS). a Data were pooled at week 12 for both trials (ELEVATE UC 52 and ELEVATE UC 12). Δ, percentage difference based on the Cochran-Mantel-Haenszel method; BMI, body mass index; CI, confidence interval; FAS, full analysis set; n, number of patients; N, number of patients in group; QD, once daily; UC, ulcerative colitis.
非 KM Figure
Figure 2Figure 2. Median ( a ) fCAL and ( b ) hsCRP levels at baseline and weeks 2, 4, 8, and 12 for patients (ELEVATE UC 52 and ELEVATE UC 12 pooled) receiving etrasimod vs placebo who achieved clinical remission at week 12, stratified by BMI. Population size of full analysis set were as follows: BMI <25 kg/m 2 : placebo QD, N = 135 and etrasimod 2 mg QD, N = 308; BMI 25–30 kg/m 2 : placebo QD, N = 80 and etrasimod 2 mg QD, N = 137; BMI >30 kg/m 2 : placebo QD, N = 45 and etrasimod 2 mg QD, N = 82. BMI, body mass index; fCAL, fecal calprotectin; hsCRP, high-sensitivity C-reactive protein; n, number of patients with nonmissing values at time point; N, number of patients in group; N/A, not applicable; QD, once daily; UC, ulcerative colitis.
非 KM Figure
Figure 3Figure 3. Median ( a ) fCAL and ( b ) hsCRP levels at baseline and weeks 2, 4, 8, and 12 for patients (ELEVATE UC 52 and ELEVATE UC 12 pooled) receiving etrasimod vs placebo who achieved clinical response at week 12, stratified by BMI. Population size of full analysis set were: BMI <25 kg/m 2 : placebo QD, N = 135 and etrasimod 2 mg QD, N = 308; BMI 25–30 kg/m 2 : placebo QD, N = 80 and etrasimod 2 mg QD, N = 137; BMI >30 kg/m 2 : placebo QD, N = 45 and etrasimod 2 mg QD, N = 82. BMI, body mass index; fCAL, fecal calprotectin; hsCRP, high-sensitivity C-reactive protein; n, number of patients with nonmissing values at time point; N, number of patients in group; QD, once daily; UC, ulcerative colitis.
非 KM Figure
Figure 4Figure 4. Median ( a ) fCAL and ( b ) hsCRP levels at baseline and weeks 2, 4, 8, and 12 for patients (ELEVATE UC 52 and ELEVATE UC 12 pooled) receiving etrasimod vs placebo who achieved endoscopic improvement at week 12, stratified by BMI. Population size of full analysis set were: BMI <25 kg/m 2 : placebo QD, N = 135 and etrasimod 2 mg QD, N = 308; BMI 25–30 kg/m 2 : placebo QD, N = 80 and etrasimod 2 mg QD, N = 137; BMI >30 kg/m 2 : placebo QD, N = 45 and etrasimod 2 mg QD, N = 82. BMI, body mass index; fCAL, fecal calprotectin; hsCRP, high-sensitivity C-reactive protein; n, number of patients with nonmissing values at time point; N, number of patients in group; QD, once daily; UC, ulcerative colitis.
非 KM Figure